Macrophages play a vital role in protecting the body against tissue damage and foreign pathogens by regulating the immune response. With the in-depth understanding of macrophages in recent years, more and more studies focus on macrophage-targeted drug delivery systems.
Based on the advancement in nanotechnology, different polymeric-based nanoparticles, dendrimers, functionalized nano cargoes, and lipid-based nano-drug delivery carriers have been applied to macrophage-targeted drug delivery systems.
Fig.1 Schematic representation of macrophage-mediated drug delivery approach.1,2
Macrophages have been explored as potential targets of drug delivery systems based on several characteristics:
Based on the unrivaled expertise and experience in immunotherapy discovery and development, Creative Biolabs provides macrophage-targeted drug delivery systems development services for global clients to speed up the development of immunotherapy projects.
Macrophage-targeted Nanoparticle Drug Delivery System
Our in-house R&D teams have expertise in providing a wide range of innovative solutions for the development of macrophage-targeted nanoparticle (NP) drug delivery systems, including nanogel drug delivery system development. Experts at Creative Biolabs are pleased to customize programs to serve specific needs with competitive pricing and high-quality standards.
Macrophage-targeted Liposome Drug Delivery System
Scientists at Creative Biolabs are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing an integrated solution for the development of macrophage-targeted liposome drug delivery systems to reduce the overall project development timeline for our clients.
Macrophage-targeted Dendrimer Drug Delivery System
Dendrimers are a kind of emerging polymeric material with three-dimension, immense branch, and well-structure. Creative Biolabs has expanded its service capabilities to offer an integrated solution for macrophage-targeted dendrimer drug delivery system development service to facilitate your project's success.
Targets for Macrophage-targeted Drug Delivery
Equipped with a team of seasoned scientists with a powerful platform designed specifically to meet very challenging requirements in macrophage development, Creative Biolabs offers fast and reliable support for choosing the most suitable target for macrophage-targeted drug delivery system development.
We specialize in the development of macrophage-targeted drug delivery systems, working closely with our clients to understand their specific research goals and needs. Our services include drug carrier design, in vitro evaluation, in vivo studies, data analysis and reporting.
The development of macrophage-targeted drug delivery systems is becoming an increasingly important direction. Such technological advances open up new possibilities for the treatment of various diseases, including cancer and inflammatory diseases. Our services focus on the design and optimization of these targeted delivery systems for various research and clinical applications.
Our company is also committed to providing researchers with a range of related products. These products include specially designed nanocarriers, drug combinations, and related kits.
Cat.No | Product Name | Product Type |
---|---|---|
MTS-0922-JF10 | Human Macrophages, Alveolar | Human Macrophages |
MTS-0922-JF99 | Human M0 Macrophages, 1.5 x 10^6 | Human M0 Macrophages |
MTS-0922-JF52 | C57/129 Mouse Macrophages, Bone Marrow | C57/129 Mouse Macrophages |
MTS-0922-JF7 | Human M2 Macrophages, Peripheral Blood, 10 x 10^6 | Human M2 Macrophages |
MTS-0922-JF34 | CD1 Mouse Macrophages | CD1 Mouse Macrophages |
MTS-1122-YF1 | MacroCargo™ Human PBMC-derived Macrophages with IL-12 (Viral System, Lentivirus) | MacroCargo™ Products |
MTS-1122-YF2 | MacroCargo™ Human PBMC-derived Macrophages with IL-21 (Viral System, Lentivirus) | MacroCargo™ Products |
MTS-1122-YF3 | MacroCargo™ Human PBMC-derived Macrophages with IFN-α (Viral System, Lentivirus) | MacroCargo™ Products |
MTS-1122-YF4 | MacroCargo™ Human PBMC-derived Macrophages with IL-1β (Viral System, Lentivirus) | MacroCargo™ Products |
MTS-1122-YF5 | MacroCargo™ Human PBMC-derived Macrophages with IL-6 (Viral System, Lentivirus) | MacroCargo™ Products |
Our carrier system is specifically designed to target macrophages, ensuring that the drug can enter the target cells efficiently, maximizing therapeutic efficacy and minimizing the impact on healthy cells. This precision targeting improves drug bioavailability and reduces systemic toxicity.
We provide customized solutions based on our customers' specific needs, including carrier type, drug loading and release mechanism. Our team will work closely with the customer to ensure that the final product perfectly meets the requirements of the research or clinical application.
Our carrier systems are not only used for drug delivery, but also for multiple functions such as imaging, monitoring and diagnostics. This multifunctionality allows us to provide services with greater potential for application in clinical research and therapy.
With strong R&D capabilities and extensive industry experience, we utilize state-of-the-art technologies, such as nanotechnology and biomaterials science, in the field of macrophage-targeted drug carrier development. This enables us to provide high-quality and efficient research support to our clients and drive rapid project progress.
Q: What types of drugs are supported by your technology platform?
A: Our technology platform supports many types of drugs, including small molecules, peptides, nucleic acids (e.g., siRNAs and mRNAs), and biological vaccines. Our vector systems can be optimized for different drug properties to ensure effectiveness and targeting.
Q: How is progress communicated and reported during implementation?
A: We value communication with our customers. After the project is initiated, we will formulate a detailed progress plan and provide regular reports to the client, including the progress of each stage, experimental results, and follow-up plans. We also welcome customers to communicate with us at any time through meetings or emails to ensure the smooth progress of the project.
Q: If I have my own R&D team, how can you work with us?
A: We are happy to cooperate with our customers' R&D teams. We can act as their technical partner and provide necessary technical guidance and experimental support. The mode of cooperation can be chosen flexibly, including but not limited to project co-development, technology transfer or providing consulting services.
Q: What is the approximate development cycle and cost budget?
A: The development cycle usually varies depending on the complexity of the project and typically takes 6 to 12 months. The cost budget will also be evaluated based on specific needs (e.g. material selection, experiment scale, technical difficulty, etc.). We will communicate thoroughly with our clients to ensure high quality services within budget.
References
Copyright © 2025 Creative Biolabs. All Rights Reserved.